When people search for "retatrutide reviews," they usually want to understand one thing: does this compound really work and how much. The trouble is that retatrutide (code name LY3437943) is an experimental research compound, not an approved medicine. As of 2026 no regulator, not the FDA (US Food and Drug Administration), not the EMA (European Medicines Agency), not Ukraine's Ministry of Health, has registered retatrutide as a drug. So "user reviews" in the classic sense are not a reliable source of information on effectiveness. Real data come from randomised controlled phase II trials, and those are what we have gathered below: documented results with real DOIs, without made-up stories or marketing promises.
What retatrutide (LY3437943) is
Retatrutide is a triple receptor agonist that activates three targets at once: GLP-1, GIP and the glucagon receptor. The first two mechanisms are already familiar from approved drugs, semaglutide (brand Ozempic, a GLP-1 agonist) and tirzepatide (brand Mounjaro, a dual GLP-1/GIP agonist). Retatrutide adds a third component, agonism at the glucagon receptor, which theoretically increases energy expenditure. The developer of the compound is Eli Lilly.
An honest note is important here. Ozempic and Mounjaro are registered prescription drugs, and any use of them must happen strictly as prescribed by a doctor; we give no self-treatment advice. Retatrutide, unlike them, has not yet completed the path of clinical trials and is not approved as a medicine. We collected a technical review of the mechanism of action and pharmacology in a separate retatrutide monograph.
"Reviews" versus data: why we show studies
The query "retatrutide reviews" reflects an understandable wish to see a real result. But for an experimental compound, anonymous forum reviews are not evidence: they cannot be verified, there is no control group, the dose is often unknown, and the source of the substance is opaque. That is exactly why evidence-based medicine relies not on individual stories but on statistics from randomised studies, where the effect is compared with placebo across hundreds of participants.
So instead of made-up "user" quotes, we give retatrutide results from two published phase II studies, one in obesity and one in type 2 diabetes. This is the closest thing to an honest "answer to the reviews" that exists at all for a compound at this stage of development.
One more nuance rarely explained in forum "reviews": the figures given were obtained through a gradual dose-escalation schedule under researchers' supervision, not through arbitrary use. The maximum effects were recorded specifically at the 12 mg dose at the end of the protocol, whereas lower doses gave proportionally smaller results. So individual figures without the context of the protocol, duration and control group are easy to be misled by. When you see a striking "minus so many percent" figure, the first question should not be "how much" but "on what schedule, for how long and compared with what," and it is the publications, not anonymous comments, that answer all of these.
Retatrutide results: a short fact block
Below are the key documented figures from two phase II studies (real data, not estimates).
| Measure | Value | Source |
|---|---|---|
| Body-weight reduction, 12 mg dose, 48 weeks (obesity) | −24.2% (placebo −2.1%) | Jastreboff et al., NEJM 2023 |
| Share of participants with weight loss ≥15% (12 mg) | 83% (placebo 2%) | Jastreboff et al., NEJM 2023 |
| HbA1c reduction, 12 mg dose, 24 weeks (T2D) | −2.02% (placebo −0.01%) | Rosenstock et al., Lancet 2023 |
| Body-weight reduction, 12 mg dose, 36 weeks (T2D) | −16.94% (placebo −3.00%) | Rosenstock et al., Lancet 2023 |
| Study phase | II (not III, not approved) | both studies |
| Most common side effects | nausea, vomiting, diarrhoea (gastrointestinal) | both studies |
Retatrutide obesity study (Jastreboff, NEJM 2023)
The key study is a phase II trial led by Ania M. Jastreboff and colleagues, published in The New England Journal of Medicine in 2023 (DOI: 10.1056/NEJMoa2301972). It is a randomised, double-blind, placebo-controlled study of 338 adults with obesity (body-mass index ≥30 kg/m², or 27–29 kg/m² with a weight-related comorbidity) without diabetes.
The highest result came from the 12 mg dose: the mean body-weight reduction at week 48 was −24.2% versus −2.1% in the placebo group. The share of participants who achieved at least 15% weight loss was 83% in the 12 mg group versus 2% in the placebo group. This is one of the largest weight-reduction effects documented for a pharmacological compound of this class in phase II. At the same time, we stress: this is an intermediate stage of development, not confirmation of effectiveness and safety at the level needed for registration.
Retatrutide in type 2 diabetes (Rosenstock, Lancet 2023)
The second large body of data is a phase II study led by Julio Rosenstock and colleagues, published in The Lancet in 2023 (vol. 402, pp. 529–544, DOI: 10.1016/S0140-6736(23)01053-X). It is a randomised, double-blind, placebo- and active-controlled study of 281 adults with type 2 diabetes, conducted in the USA.
At the 12 mg dose, the reduction in glycated haemoglobin (HbA1c) at week 24 was −2.02% versus −0.01% in the placebo group. In parallel, a body-weight reduction was observed, up to −16.94% at week 36 versus −3.00% in the placebo group. The authors note that the safety profile was broadly consistent with the GLP-1 agonist and dual GLP-1/GIP agonist classes, that is, without unexpected signals for this mechanism of action, but, again, within phase II.
Safety and limitations: what the data do NOT prove
The most important part of any honest material about an experimental compound is the limitations.
- There is no approved drug. Retatrutide is not registered as a medicine in any jurisdiction. All the figures above are results of research protocols, not instructions for use.
- This is phase II, not III. Phase II studies assess effect and dosing in relatively small groups over a limited time. Confirmation of long-term safety and effectiveness is the task of large phase III studies, which are ongoing.
- The side effects are real. The most frequent adverse events in both studies were gastrointestinal, nausea, vomiting, diarrhoea, and were mostly dose-dependent. Assessing rare and delayed risks requires longer observation.
- This is not medical advice. The data given are not a recommendation to use, dose or acquire any substance to affect health.
In other words, the correct answer to the query "retatrutide reviews" is this: the available phase II data look powerful in the size of the effect, but they do not replace completed phase III studies, regulatory approval or a consultation with a doctor.
Research-grade retatrutide: why purity and a COA matter
Since retatrutide remains a research compound, it can be of interest to laboratories and scientists in a research-use-only format. In this context the quality of the material itself is critical: confirmed identity, purity and the presence of a certificate of analysis (COA). Without a documented COA, any "results" cannot be matched to what is actually in the vial.
We provide research-grade retatrutide with an emphasis specifically on transparency of specifications; details of purity and accompanying documentation are on the research-grade retatrutide card. For deeper technical context, the triple-agonism mechanism, a review of the clinical program and links to primary sources, see our retatrutide monograph.
